These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2477 related items for PubMed ID: 11565517

  • 1. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group.
    N Engl J Med; 2001 Sep 20; 345(12):851-60. PubMed ID: 11565517
    [Abstract] [Full Text] [Related]

  • 2. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar 20; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.
    Ann Intern Med; 2003 Apr 01; 138(7):542-9. PubMed ID: 12667024
    [Abstract] [Full Text] [Related]

  • 4. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.
    N Engl J Med; 2001 Sep 20; 345(12):870-8. PubMed ID: 11565519
    [Abstract] [Full Text] [Related]

  • 5. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.
    Nephrol Dial Transplant; 2000 Apr 20; 15(4):487-97. PubMed ID: 10727543
    [Abstract] [Full Text] [Related]

  • 6. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF, Curran MP, Goa KL, Perry CM.
    Drugs; 2004 Apr 20; 64(9):999-1028. PubMed ID: 15101793
    [Abstract] [Full Text] [Related]

  • 7. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group.
    Nephron Clin Pract; 2008 Apr 20; 108(4):c291-7. PubMed ID: 18434751
    [Abstract] [Full Text] [Related]

  • 8. A clinical trial in type 2 diabetic nephropathy.
    Lewis EJ, Hunsicker LG, Rodby RA, Collaborative Study Group.
    Am J Kidney Dis; 2001 Oct 20; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
    [Abstract] [Full Text] [Related]

  • 9. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators.
    N Engl J Med; 2001 Sep 20; 345(12):861-9. PubMed ID: 11565518
    [Abstract] [Full Text] [Related]

  • 10. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E.
    Dtsch Med Wochenschr; 2004 Jan 02; 129(1-2):13-8. PubMed ID: 14703575
    [Abstract] [Full Text] [Related]

  • 11. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
    Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ.
    J Am Soc Nephrol; 2005 Oct 02; 16(10):3027-37. PubMed ID: 16120823
    [Abstract] [Full Text] [Related]

  • 12. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
    Frei A, Palmer AJ, Burnier M, Hess B.
    Praxis (Bern 1994); 2006 Mar 15; 95(11):401-8. PubMed ID: 16570646
    [Abstract] [Full Text] [Related]

  • 13. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM, Germino FW, Smith D.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep 15; 6(2):84-9. PubMed ID: 16470487
    [Abstract] [Full Text] [Related]

  • 14. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
    Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, Bianchetti MG.
    Kidney Int; 2003 Oct 15; 64(4):1450-4. PubMed ID: 12969165
    [Abstract] [Full Text] [Related]

  • 15. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
    Ruilope LM.
    Am J Hypertens; 1997 Dec 15; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
    [Abstract] [Full Text] [Related]

  • 16. Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
    Ann Intern Med; 2003 Apr 01; 138(7):I43. PubMed ID: 12667050
    [No Abstract] [Full Text] [Related]

  • 17. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ, Valentine WJ, Ray JA.
    Int J Clin Pract; 2007 Oct 01; 61(10):1626-33. PubMed ID: 17877649
    [Abstract] [Full Text] [Related]

  • 18. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ.
    Nephrol Dial Transplant; 2003 Oct 01; 18(10):2059-66. PubMed ID: 13679481
    [Abstract] [Full Text] [Related]

  • 19. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH.
    Diabetes Care; 2004 Aug 14; 27(8):1897-903. PubMed ID: 15277414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 124.